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Abstract
Fructose is a major component of dietary sugar and its overconsumption exacerbates key 
pathological features of metabolic syndrome. The central fructose-metabolising enzyme is 
ketohexokinase (KHK), which exists in two isoforms: KHK-A and KHK-C, generated through 
mutually exclusive alternative splicing of KHK pre-mRNAs. KHK-C displays superior affinity for 
fructose compared with KHK-A and is produced primarily in the liver, thus restricting fructose 
metabolism almost exclusively to this organ. Here we show that myocardial hypoxia actuates 
fructose metabolism in human and mouse models of pathological cardiac hypertrophy through 
hypoxia-inducible factor 1α (HIF1α) activation of SF3B1 and SF3B1-mediated splice switching 
of KHK-A to KHK-C. Heart-specific depletion of SF3B1 orgenetic ablation of Khk, but not Khk-
A alone, in mice, suppresses pathological stress-induced fructose metabolism, growth and 
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contractile dysfunction, thus defining signalling components and molecular underpinnings of a 
fructose metabolism regulatory system crucial for pathological growth.
Heart failure is a leading cause of death worldwide. It is often preceded by hypertrophic 
growth of the organ as it strains to maintain function under conditions of pathologic stress1 
and is associated with an increased demand for oxygen, owing to changes in coronary 
resistance, cardiac vascularisation and perfusion2. The ensuing state of hypoxia activates 
hypoxia-inducible factor (HIF)1α that mediates adaptive transcriptional responses to low-
oxygen tension3 to support cardiomyocyte growth, myocardial angiogenesis and 
reprogramming of metabolism4. Unremitted pathologic stress leads ultimately to functional 
deterioration of the heart with the clinical signs and symptoms of heart failure5.
Given that both HIF1α transcription and alternative pre-mRNA splicing are central to the 
control of metabolism, we embarked on a systematic and functional analysis of HIF1α-
dependent splice factor expression and pre-mRNA splicing in pathologic cardiac 
hypertrophy. We identified splice factors as HIF1α targets, which prompted the analysis of 
their RNA targets, unveiling mechanistic and functional linkages between HIF1α, splice 
factor 3b subunit 1 (SF3B1), KHK-C splice isoform production and fructose metabolism in 
cardiac hypertrophy.
The HIF1α–SF3B1–KHK-C axis
To deduce changes in both gene expression and alternative splicing as a function of Hif1α, 
we followed the experimental workflow illustrated in Extended Data Fig. 1a. RNA isolated 
from normoxic and hypoxic neonatal mouse cardiomyocytes (NMCs), depleted (or not) of 
Hif1α by specific short hairpin RNAs (shHif1α), was subjected to a splice-junction 
microarray analysis. Genes exhibiting a Hif1α-dependent expression profile were manually 
checked for an involvement in pre-mRNA splicing and, in parallel, matched to a list of 329 
unique genes comprised of validated and in silico-predicted splice factors6–8 
(Supplementary Fig. 1 and Supplementary Table 1). Twenty genes with characteristics of 
splice factors/regulators displayed a Hif1α-dependent expression pattern (Fig. 1a), of which 
four, C1qbp, Hnrnph3, Jmjd6 and Sf3b1, contained conserved hypoxia-responsive elements 
(HREs) in their promoters (Extended Data Fig. 1b).
Data derived from the splice-junction microarray analysis were also interrogated for changes 
in gene splicing as a function of Hif1α and further filtered for their potential association to 
metabolism, leading to Ard1 (also known as Naa10), Hk1, Khk, and Pfkfb3, which exhibited 
the most consistent and significant changes (Fig. 1b). The Hif1α dependency of Khk 
alternative splicing implied a link between hypoxia and fructose metabolism, especially 
since the dominant Khk isoform induced by hypoxia, Khk-C, has a superior activity over 
Khk-A9 (Supplementary Fig. 2).
Analysis of Khk alternative splicing in NMCs by real-time PCR (RT–PCR) revealed Hif1α-
mediated, Sf3b1-dependent induction of Khk-C mRNAs, while mRNA levels of Khk-A 
declined (Fig. 1c and Extended Data Fig. 1c–e). Isoproterenol treatment yielded similar 
results (Extended Data Fig. 1f, g). Also, in mouse models of cardiac hypertrophy, 
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specifically one-kidney one-clip (1K1C), trans-aortic constriction (TAC) and isoproterenol 
infusion, Khk-C mRNA and protein production increased over sham-treated control mice 
(Fig. 1d, e and Extended Data Fig. 1h–n). Hif1α target and hypertrophic marker gene 
expression were dramatically increased in all three cardiomyopathy models (Extended Data 
Fig. 1o and Supplementary Fig. 3a–c).
Analysis of HIF1α, SF3B1 and KHK-C in ventricular biopsies of aortic stenosis or 
hypertrophic cardiomyopathy (HCM) patients corroborated the results obtained in mice both 
at the level of mRNA and protein expression (Fig. 1f–h and Extended Data Fig. 1p). 
mRNAs of HIF1α targets and hypertrophic markers were also induced (Extended Data Fig. 
1q and Supplementary Fig. 3d). Thus, HIF1α, SF3B1 and KHK-C are coordinately 
upregulated in different mouse models of cardiac hypertrophy and biopsies of human 
cardiomyopathy patients.
The HIF1α target SF3B1 mediates splicing of KHK
Sf3b1 appears to represent a direct Hif1α target. First, treatment of NMCs with 
phenylephrine or isoproterenol, known inducers of Hif1α and Hif1α-target genes10, 
increased Sf3b1 mRNA expression in a Hif1α-dependent manner (Extended Data Fig. 2a). 
Second, Sf3b1 mRNA expression also increased upon depletion of the Von Hippel–Lindau 
protein (pVhl) or ectopic expression of HIFlα lacking the oxygen-dependent degradation 
domain (HIF1αΔODD) (Extended Data Fig. 2b). Third, the promoter of SF3B1 contains a 
highly conserved HRE (Extended Data Fig. 2c). Fourth, expression of HIF1αΔODD 
activated a mouse wild-type Sf3b1-promoter-luciferase reporter but not the corresponding 
reporter harbouring a mutant HRE (Fig. 2a). Fifth, chromatin immunoprecipitation (ChIP) 
assays demonstrate an association of Hif1α with the HRE in the Sf3b1 promoter in native 
chromatin (Fig. 2b).
Next we measured the incorporation of radioactively labelled [3H]leucine in NMCs depleted 
of Sf3b1 and exposed to various treatments including phenylephrine or isoproterenol 
(Extended Data Fig. 2d), expression of HIF1αΔODD (Extended Data Fig. 2e), hypoxia 
(Extended Data Fig. 2f) or simultaneous depletion of pVhl (Extended Data Fig. 2g). We 
observed that [3H]leucine incorporation (Extended Data Fig. 2i–k), myosin heavy chain α/β 
mRNA ratio (Extended Data Fig. 2l–o) and cell size (Extended Data Fig. 2p) changed as a 
function of Sf3b1. Other components of the U2 small nuclear ribonucleoprotein (U2 snRNP) 
complex, namely Sf3b2, Sf3b3 and Sf3a3, neither increased in abundance in response to 
Hif1α expression nor did they affect, when downregulated by different shRNAs, to a 
measurable extent, Hif1α-stimulated cell growth (Extended Data Fig. 2q, r and 
Supplementary Fig. 4).
Also, known parameters of Hif1α-driven metabolism including extracellular acidification 
rate (ECAR; an indicator lactate production) and oxygen consumption rate (OCR; an 
indicator of oxidative phosphorylation) changed in a Sf3b1-dependent manner in NMCs. At 
basal levels, ECAR was not affected by depletion of Sf3b1 but increased upon addition of 
isoproterenol (Extended Data Fig. 2s, t). OCR was repressed, as expected, in isoproterenol-
treated cells upon addition of either oleic acid or carbonyl cyanide-4-(trifluoromethoxy)-
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phenylhydrazone, an effect diminished by depletion of Sf3b1 (Extended Data Fig. 2u). 
Ectopic expression of HIF1αΔODD produced similar effects on ECAR and OCR as 
isoproterenol (Extended Data Fig. 2v–z), while depletion of Sf3b1 alone had no effect 
(Supplementary Fig. 5). In sum, these results suggest a key contributory role for Sf3b1 in 
Hif1α-mediated growth and metabolic programs.
Sf3b1 participates in the catalysis of splicing11, can be crosslinked to the 5′ and 3′ of the 
branch point adenosine12, and displays differential effects on specific splice targets under 
conditions of reduced function13,14. Indeed, splice-junction analysis revealed widespread 
effects on both alternative splicing and gene expression that included changes in Khk 
isoform expression when Sf3b1 was depleted in hypoxic NMCs (Supplementary Tables 2 
and 3). RNA-immunoprecipiations of Sf3b1 from extracts of NMCs exposed to hypoxia or 
HIF1αΔODD overexpression, demonstrate that Sf3b1 occupies RNA sequences upstream of 
exon 3C (and not of exon 3A) of Khk pre-mRNA in hypoxia but not normoxia (Fig. 2c). 
Upon depletion of Hif1α, Sf3b1 was redirected towards branch-point sequences of exon 3A 
(Fig. 2c). This suggests that Sf3b1 association with RNA sequences upstream of exon 3C of 
Khk requires Hif1α-signalling.
Sf3b1 acts as a direct mediator of Khk splicing as its overexpression caused a shift from 
Khk-A to Khk-C (Extended Data Fig. 3a). Selective depletion of endogenously (but not 
exogenously) produced Sf3b1 prevented this shift (Extended Data Fig. 3a). Quantitative 
PCR (qPCR) analysis confirmed the overexpression and/or reduction of Sf3b1 mRNAs 
where expected (Extended Data Fig. 3b). Concomitant with the shift in Khk isoform 
expression towards Khk-C, cell growth was induced (Extended Data Fig. 3c). Neither the 
overproduction of SF3A3 or SF3B3 (Extended Data Fig. 3d, e), nor the depletion of Sf3a3, 
Sf3b3 or Sf3b2 by corresponding shRNAs, generated a similar robust splice shift towards 
Khk-C despite efficient depletion of the respective proteins (Extended Data Fig. 3f, g and 
Supplementary Fig. 4). Cell growth was also not affected by SF3A3 or SF3B3 expression 
(Extended Data Fig. 3h).
Next we proceeded with mass-spectrometry-based metabolomic profiling of hexose-
phosphates in NMCs expressing HIF1αΔODD in the absence or presence of shSf3b1. We 
observed profoundly increased levels of fructose-1-phosphate (F1P) and glucose-6-
phosphate in response to HIF1α activation (Fig. 2d), but only the level of the former was 
Sf3b1-dependent (Fig. 2d). In accord with increased levels of F1P, HIF1αΔODD also 
increased total cellular Khk activity by 3.6-fold compared to control NMCs (Fig. 2e). In a 
comparative analysis, overexpressed human KHK-C displayed, in NMCs depleted for 
endogenous Khk, a 3.7-fold higher kinase activity than KHK-A (Extended Data Fig. 3i, j). 
Thus, activation of the Hif1α-Sf3b1 axis activates Khk-C to stimulate F1P production.
To assess whether increased levels of F1P are derived from external fructose or from 
conversion of glucose via the polyol pathway15, we supplied NMC culture media with 
[13C]fructose and unlabelled glucose or [13C]glucose and unlabelled fructose and measured 
[13C]F1P production. [13C]F1P levels increased upon HIF1αΔODD expression selectively 
in NMCs cultured with [13C]fructose and unlabelled glucose but not [13C]glucose and 
unlabelled fructose in a manner dependent on Sf3b1 (Fig. 2f). Moreover, KHK-C, but not 
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KHK-A, expression induced accumulation of [13C]F1P levels in a time-dependent fashion in 
NMCs cultured with [13C]fructose (Extended Data Fig. 3k). Glut5 fructose transporter 
mRNA expression was likewise induced by KHK-C and HIF1αΔODD (Extended Data Fig. 
3l).
Khk-C is also a critical downstream mediator of Hif1α-induced cell growth as selective 
depletion of Khk-C, but not Khk-A, rescued HIF1αΔODD-induced cardiomyocyte growth 
(Fig. 2g and Extended Data Fig. 3m). Knockdown efficiency and isoform specificity of the 
corresponding shRNAs targeting Khk isoforms was confirmed by qPCR (Extended Data 
Fig. 3n). Taken together, Sf3b1 appears to be a direct mediator of Khk pre-mRNA splicing, 
resulting in Khk-C expression, increased Khk activity, fructose uptake and cell growth.
Expression of KHK-C promotes anabolic metabolism
To characterize metabolic phenotypes in NMCs associated with activation of the HIF1α–
SF3B1–KHK-C axis and as a function of fructose availability, we performed metabolomic 
profiling. These efforts established the following experimental points. First, in the presence 
of fructose and glucose, HIF1αΔODD expression increased glycolysis (for example, hexose-
phosphates), amino acid metabolism and biosynthesis (for example, dexfosfoserine, 
aspartate, arginine), the non-oxidative pentose-phosphate pathway (PPP; for example, 
sedoheptulose-7-phosphate, pentose phosphates) and to a lesser degree also the oxidative 
PPP (for example, 6-phospho-D-gluconate, pentose phosphates) and intermediates of 
DNA/RNA biosynthesis (for example, N-formyl-GAR, folate, deoxyuridine) (Fig. 3). 
Changes in redox balance are exemplified by lower levels of NADPH, NADH and of the 
reduced state of glutathione (GSSG) (Fig. 3, lanes 4 and 5). Reduced levels of these 
metabolites are probably the result of extensive utilization of reducing equivalents for 
macromolecular biosynthesis16. Second, depletion of Khk-C (but not Khk-A) reverted 
HIF1αΔODD-induced metabolic changes (Fig. 3, compare lane 11 with 5 and 4), while its 
overexpression mimicked them (Fig. 3, compare lane 1–3 and 4–5). Third, when KHK-C 
was overexpressed under fructose-lacking conditions, levels of glycolytic and PPP 
metabolites decreased and the reduction of NADPH and NADH was less pronounced (Fig. 
3, compare lane 2 and 3; Extended Data Fig. 4a). Hence, exogenous fructose contributes 
significantly to the metabolic effects mediated by Khk-C.
In accord with the above, we detected [3H] radiolabel derived from [3H]fructose in the 
RNA, DNA and protein fractions of NMCs in a HIF1αΔODD- and KHK-C-dependent 
manner (Extended Data Fig. 4b). Expression of KHK-C stimulated also glucose uptake in 
the presence of fructose (Extended Data Fig. 4c). Moreover, [3H]leucine incorporation into 
NMCs increased as a function of fructose availability in a KHK-C-dependent fashion 
(Extended Data Fig. 4d). Increasing glucose availability in the presence of fructose had 
similar effects (Extended Data Fig. 4d). Immunoblotting confirmed the expected expression 
pattern of KHK-A and KHK-C (Supplementary Fig. 6a). These results suggest a critical role 
for KHK-C in HIF1α-dependent metabolic reprogramming and growth.
Since phosphorylation of fructose by Khk-C is unrestrained, it could contribute to ATP-
depletion as shown previously in liver17, thereby limiting ATP-driven allosteric inactivation 
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of glycolysis at the level of phosphofructokinase (PFK)18,19. When HIF1αΔODD was 
overexpressed in NMCs, the ADP/ATP ratios increased (Extended Data Fig. 4e). 
Simultaneous depletion of either Sf3b1 or Khk-C (but not Khk-A) prevented this (Extended 
Data Fig. 4e). Khk-C but not Khk-A, when overexpressed, enhanced ADP/ATP ratios 
(Extended Data Fig. 4e). Thus, activation of the HIF1α–SF3B1–KHK-C axis increases 
ADP/ATP ratios.
Hypoxia or activation of HIF1α drives an accumulation of lipids in heart hypertrophy10,20. 
Since the F1P product DHAP is important for formation of the glycerol backbone in 
triglyceride synthesis, we tested the Khk-C-dependency of this phenomenon by Oil Red O 
staining of lipid droplets in oleic-acid-treated NMCs. Overexpression of HIF1αΔODD or 
exposure to hypoxia induced lipid droplet formation, which was prevented upon depletion of 
Khk-C but not Khk-A (Extended Data Fig. 4f–h). Similar results were obtained when lipid 
levels were quantified with Nile Red (Supplementary Fig. 6b, c). Khk-C, but not Khk-A, 
was also required for phenylephrine-induced lipid accumulation (Supplementary Fig. 6d). 
Fructose carbon contributes to triglyceride synthesis in NMCs as measured by the amount of 
fructose-derived [3H] in the lipid fraction of NMCs expressing HIF1αΔODD 
(Supplementary Fig. 6e). Downregulation of Khk-A had no effect, but depletion of either 
Khk-C, Glut5 or Sf3b1 prevented HIF1α-driven conversion of fructose carbon into lipids 
(Supplementary Fig. 6e, f). In a gain-of-function experiment, over-expression of KHK-C 
promoted fructose carbon to lipid conversion while KHK-A expression did not 
(Supplementary Fig. 6e).
We also investigated the contribution of the two different Khk-isoforms to Hif1α-driven 
changes in OCR and ECAR in NMCs (Extended Data Fig. 4i–l). Khk-A depletion affected 
neither the ECAR nor the OCR of HIF1αΔODD-expressing cells (Extended Data Fig. 4i), 
while depletion of Khk-C did (Extended Data Fig. 4j). In the absence of HIF1αΔODD, 
neither Khk-A nor Khk-C depletion alone demonstrated any measurable effects on ECAR or 
OCR (Supplementary Fig. 6g, h). In a converse experiment, overexpression of KHK-A 
alone had little, if any, effect on these parameters while KHK-C overexpression increased 
ECAR and decreased OCR (Extended Data Fig. 4k, l). Thus, by stimulating fructose 
metabolism in cardiomyocytes, Khk-C expression promotes conversion of fructose carbon to 
lipids, suppresses mitochondrial oxidative phosphorylation and increases glycolysis.
Cardiac growth and dysfunction depends on Sf3b1
Next we assessed whether myocardial fructose and glucose uptake is induced in an in vivo 
model of cardiac hypertrophy (Extended Data Fig. 5a). When TAC-treated and sham-
operated control mice were simultaneously exposed to [3H]fructose and [14C]deoxyglucose, 
they accumulated to higher levels in diseased hearts (Extended Data Fig. 5b, c). Hearts of 
mice after 1K1C surgery (Extended Data Fig. 5d), demonstrated a 2.5-fold increase of 
fructose levels (Extended Data Fig. 5e). [14C]fructose or [14C](deoxy)glucose uptake was 
also stimulated under conditions of hypertrophy in ex vivo ventricular tissue (Extended Data 
Fig. 5f, g). In line with this, Glut5 expression was induced in these hypertrophy models 
(Extended Data Fig. 5h, i) in hearts of isoproterenol-treated mice and in left-ventricular 
biopsies of aortic stenosis and HCM-patients (Extended Data Fig. 5j–l). In contrast, 
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expression of aldose reductase (AKR1B1), which converts glucose to sorbitol in the polyol 
pathway, was not induced in the latter samples (Extended Data Fig. 5k, l). Thus, cardiac 
hypertrophy is associated with increased fructose levels and uptake.
To study the Sf3b1-dependency of these phenomena in response to pathologic stress, we 
designed a viral-based vector system enabling ventricular-specific knockdown of Sf3b1 that 
is based on an AAV9 backbone containing a U6 promoter followed by a TATA-lox site, a 
CMV promoter driving eGFP, another TATA-lox site and shRNAs targeting Sf3b1 (Fig. 4a). 
We constructed two viruses each expressing different shRNAs targeting Sf3b1 (AAV9-fl/fl-
shSf3b1#1 and AAV9-fl/fl-shSf3b1#2). Validation of these recombinant viruses was 
performed both in vitro in NMCs and in vivo in Mlc2v-cre+ and Mlc2v-cre− mice (Extended 
Data Fig. 5m, n and Supplementary Fig. 7a–d).
While injection of AAV9-fl/fl-shSf3b1#1 into Mlc2v-cre+ or Mlc2v-cre− mice failed to 
cause any effects on ventricular size in sham-operated mice, AAV9-fl/fl-shSf3b1#1 injection 
protected Mlc2v-cre+ but not Mlc2v-cre− littermates from 1K1C-induced cardiac 
hypertrophy (Fig. 4b) and diastolic dysfunction (Fig. 4c and Extended Data Table 1). Like 
hypertrophic growth and function, the increase in fructose levels was also dependent on 
Sf3b1 (Fig. 4d). Immunoblotting of lysates from these sham- or 1K1C-operated Mlc2v-cre− 
and Mlc2v-cre+ mice confirmed that Sf3b1 was depleted where expected, preventing the 
generation of Khk-C isoform in ventricles of 1K1C-treated Mlc2v-cre+ mice (Fig. 4e).
We also analysed the role of Sf3b1 in the TAC model. Application of both AAV9-fl/fl-
shSf3b1#1 and AAV9-fl/fl-shSf3b1#2 viruses protected Mlc2v-cre+ but not Mlc2v-cre− 
littermates from cardiac hypertrophy (Fig. 4f; Extended Data Fig. 5o and Extended Data 
Table 1) and systolic dysfunction (Fig. 4g; Extended Data Fig. 5p and Extended Data Table 
1). Immunoblotting confirmed that Sf3b1 was downregulated and prevented the switch to 
the Khk-C isoform in response to TAC-induced pathologic stress in hearts of Mlc2v-cre+ 
mice (Fig. 4h and Extended Data Fig. 5q). These results suggest that Sf3b1 is required for 
the development of pathologic cardiac hypertrophy.
Deletion of Khk protects from cardiac growth
To assess the importance of Khk-C in cardiac hypertrophy and function in the context of 
pathologic stress, we investigated two genetic mouse models, which were subjected to TAC 
and 1K1C stresses. Khk-A−/− mice only express Khk-C, whereas Khk-A/C−/− mice are 
deleted for both isoforms21. Exposure of wild-type and Khk-A−/− mice to TAC treatment 
induced cardiac hypertrophy and systolic dysfunction in both mouse strains (Extended Data 
Fig. 6a–e and Extended Data Table 2). ATP measurements in left ventricles of sham- or 
TAC-treated wild-type and Khk-A−/− mice revealed a reduction of ATP levels in hearts after 
TAC compared to control mice (Extended Data Fig. 6f).
Hearts of Khk-A/C−/− mice, when exposed to TAC, did not display signs of hypertrophy or 
systolic dysfunction (Extended Data Fig. 6g–k and Extended Data Table 2). Moreover, ATP 
levels remained unchanged in Khk-A/C−/− mice exposed to TAC (Extended Data Fig. 6l). 
All TAC-treated hearts accumulated Hif1α and Sf3b1 in the left ventricle (Extended Data 
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Fig. 6m, n). Khk-C expression was only detectable in TAC-treated hypertrophied ventricles, 
but not in the corresponding hearts from Khk-A/C−/− mice (Extended Data Fig. 6m, n).
1K1C treatment of Khk-A−/− and Khk-A+/+ mice caused significant left-ventricular growth 
(Fig. 5a, b; Extended Data Fig. 6o–q and Extended Data Table 3) and diastolic dysfunction 
(Fig. 5c and Extended Data Table 3). Hif1α and Sf3b1 levels were induced in left ventricles 
of both 1K1C-treated strains, whereas Khk-A expression in sham-treated control mice was 
depleted as expected (Fig. 5d). Additional deletion of Khk-C protected hearts of these 
pathologies (Fig. 5e–g; Extended Data Fig. 6r–t and Extended Data Table 3). 
Immunoblotting confirmed activation of Hif1α and Sf3b1 upon pathologic stress, and that 
Khk-C was only expressed in wild-type and Khk-A−/− but not in Khk-A/C−/− ventricles (Fig. 
5h). Arterial blood pressure was similar in these mouse strains following 1K1C treatment 
(Extended Data Fig. 6u, v). In sum, only deletion of Khk-A in combination with Khk-C, but 
not Khk-A alone, prevents the development of pathologic growth and cardiac dysfunction 
upon different stresses.
Discussion
Our results demonstrate that fructose metabolism can be provoked in the heart by pathologic 
stimuli through HIF1α activation of SF3B1-mediated splicing of KHK pre-mRNA 
(Extended Data Fig. 7). The potential general importance of these findings draw on the 
central role occupied by HIF1α in human disease, highlighting the HIF1α–SF3B1–KHK-C 
axis as a promising therapeutic target.
Splicing output of the HIF1α target SF3B1, which contributes to intron removal by 
anchoring pre-mRNA onto the spliceosome12, is sensitive to changes in the abundance of 
SF3B113,22. This feature of SF3B1 to expand and/or change splice target spectrum as a 
function of abundance may be exploited by HIF1α to affect KHK-C production. That the 
latter is less sensitive to changes in the levels of other factors of the U2snRNP complex 
investigated here implies that SF3B1 is either limiting for U2snRNP assembly/function or 
occupies a specific role in this context. Irrespective, this process is likely influenced by 
additional positive- and/or negative-acting factors, as has been demonstrated for PKM223.
The criticality of KHK-C function in pathologic cardiac growth may manifest at multiple 
levels. Unrestrained KHK-C-driven phosphorylation of fructose may limit ATP levels and 
thus restrict ATP-mediated negative feedback inhibition of PFK, facilitating high glycolytic 
flux24. The latter may be further enhanced by an increased availability of F1P, as this 
metabolite has been shown to induce glucokinase and pyruvate kinase, at least in the liver25. 
Apart from positively affecting glucose metabolism, KHK-C and fructose availability also 
increased nucleic acid, lipid and protein biosynthesis, which may support growth. Although 
our work points to a fructose-metabolism-related function of KHK-C in cardiac 
hypertrophy, the source of fructose could, under certain circumstances, vary and originate 
alternatively from glucose15. In addition, yet-to-be-discovered functions of KHK-C 
unrelated to fructose metabolism (that may, for example, relate to gene regulatory activities) 
could contribute to cell growth control26.
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Biopsies of heart disease patients demonstrate increased expression of HIF1α, SF3B1 and 
KHK-C. Since aortic stenosis and diabetes are frequent comorbidities in senescent humans27 
and diabetic patients tend to have also higher fructose levels in serum28, the impact of the 
HIF1α-SF3B1-KHK-C axis in these patients might be particularly important. With respect 
to other disease states, SF3B1 is found recurrently mutated in human cancers12. It is 
conceivable that some of these cancer-associated mutations affect alternative splicing of 
KHK and fructose metabolism in cancer cells independent of hypoxia, thereby contributing 
to tumour development.
METHODS
Human ventricular biopsies
Left-ventricular tissues were obtained from patients with hypertrophic cardiomyopathy and 
aortic stenosis (Supplementary Table 4) and healthy controls. Additional left-ventricular 
biopsies were provided by W. Linke (University of Münster). Clinical and demographical 
data from the corresponding patients were previously published29. All procedures were in 
compliance with local ethical committees. An informed consent was obtained from all 
patients included in the study.
Mouse strains
Khk-A−/− and Khk-A/C−/− mice were obtained from A. Asipu (University of Leeds) and R. 
Johnson (University of Colorado). MLC2v-cre line was from J. Chen (University of 
California). All mice were maintained in a conventional animal facility at RCHCI and EPIC, 
ETH Zürich. Maintenance and animal experimentation were in accordance with the Swiss 
Federal Veterinary Office (BVET) guidelines. Data presented in this manuscript represent 
studies with male mice. After baseline echocardiography mice were randomly distributed to 
sham or treatment groups. Animal surgeries and echocardiography was performed blinded, 
that is the involved veterinarian was not aware of the genotype of the mice before or during 
operation. Animal numbers for experiments were chosen based on expected mortality rates 
and phenotypical or functional changes of hearts in wild-type mice due to treatment/surgery. 
Animals were excluded from the study in case of death before the experimental endpoint or 
based on the evaluation of pain using a standardized score sheet, approved by BVET.
One-kidney, one-clip
Six- to seven-week-old Khk-A−/−, Khk-A/C−/− and corresponding Khk-A+/+ and Khk-A/C+/+ 
male mice with a pure C57/BL6J background as well as Mlc2v-cre+ and Mlc2v-cre− male 
mice with a C57/BL6J 129S mixed background were anaesthetized and surgery was 
performed as previously described10 by inhalation of isoflurane (4% in oxygen, 1 l min−1). 
A sham procedure, which included the entire surgery with the exception of artery clipping, 
was applied to control mice.
Trans-aortic constriction
10–12-week-old Khk-A−/−, Khk-A/C−/− and corresponding Khk-A+/+ and Khk-A/C+/+ male 
mice as well as Mlc2v-cre+ and Mlc2v-cre− male mice were subjected to pressure overload 
by trans-aortic constriction (TAC) through constriction of the descending aorta as 
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described30. The mice were monitored for 14–18 days after surgery, and their heart 
functions determined by echocardiography.
In vivo isoproterenol delivery
Alzet model 2002 mini-osmotic pumps (Alzet) were filled with isoproterenol, and were set 
to deliver at 30 mg kg−1 per day for 14 days in C57/BL6J wild-type mice. Pumps were then 
implanted into 9–10-week-old male mice under isoflurane anaesthesia as previously 
described10.
Echocardiography
Transthoracic echocardiography was performed using a 30 MHz probe and the Vevo 770 
Ultrasound machine (Visualsonics) under mild anaesthesia with 1.5% isoflurane as 
previously described31.
Direct arterial blood pressure measurements in mice
The arterial blood pressure measurements in mice were performed as described 
previously32. Blood pressure was monitored for about 1 h in awake animals that were 
unconstrained.
Isolation and maintenance of primary neonatal mouse cardiomyocytes
Isolation of neonatal mouse cardiomyocytes was performed as previously described10. 
Experiments involving HIF1α, SF3B1 and KHK-C were performed with maintenance 
medium supplemented with physiologic concentrations of glucose (5 mM) and fructose (25 
μM). The medium was changed daily. Pharmacological treatment was done with 
phenylepinephrine at a concentration of 100 μM and with isoproterenol at 10 μM for 48 h 
before preparation of SDS samples or processing for RNA isolation.
Lentivirus production and transduction
Lentiviral particles were produced in HEK-293T cells as previously described33. HEK-293T 
cells were purchased from American Type Culture Collection (ATCC) and regularly 
checked for mycoplasma contamination using a PCR-based myocoplasma detection kit 
(Sciencell). Cells were transduced with lentivirus 3 h after isolation by adding virus-
containing supernatants to the cell culture medium and incubating cells at 37 °C/5% CO2 
overnight.
Transient transfection
The pcDNA3 Sf3b1 construct was transiently transfected by using the Lipofectamin 2000 
(Invitrogen) in 2-day-old NMCs according to the manufacturer’s protocol. Cells were 
harvested and analysed 36 h after transfection.
AAV9-fl/fl-shSf3b1
For the generation of the viral constructs, we cloned two shRNAs targeting Sf3b1 in a pSico 
vector where the U6 promoter driven shRNA expression is Cre–lox regulated34. The shRNA 
sequences were the following: AAV9-fl/fl-shSf3b1#1, sense (5′–
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3′):TGCATCGTCCTCCAAAGATTTTCAA 
GAGAAATCTTTGGAGGACGATGCTTTTTTC, antisense (5′–3′): TCGAG 
AAAAAAGCATCGTCCTCCAAAGATTTCTC TT GAAAATCTTTGGAGG 
ACGATGCA; AAV9-fl/fl-shSf3b1#2, sense (5′–3′): TG CTGCCTTACGTC 
AGATTATTCAAGAGATAATCTGACGTAAGGCAGCTTTTTTC, antisense (5′–3′): 
TCGAGAAAAAAGCTGCCTTACGTCAGATTATCTCTTGAATAA 
TCTGACGTAAGGCAGCA.
After in vitro validation of shRNA efficiency using AdenoCre expression to induce Cre-
mediated recombination and activation of shSf3b1 expression, the region bearing the U6 
promoter, the shRNA and the TATA-lox sites of the pSico construct was amplified and 
ligated into NheI/XhoI linearized AAV-bGH(+) vector. Viral amplification was done by 
Vectorbiolabs. AAV9 viruses were injected at a concentration of 1.2 × 1013 genome copies 
(GC) per kg body weight into tail veins of Mlc2v-cre+ or Mlc2v-cre− mice.
Plasmid constructions
The pLenti-pgk-HIF1αΔODD puro lentiviral expression vector was generated by subcloning 
the HIF1αΔODD fragment from a pcDNA3-HA-HIF1αΔODD(401–603) plasmid35 as 
described previously36. The KHK-A and KHK-C overexpression constructs were generated 
by subcloning KHK-A and KHK-C from the pET11a-KHK-A and pET11a-KHK-C 
expression constructs (provided by A. Asipu) into the Gateway Entry vector pENTR1a and 
by LR-reaction in the pLenti-pgk-puro lentiviral expression vector. As a corresponding 
control the pLenti-pgk puro empty vector was used. SF3A3 and SF3B3 over-expression 
constructs were generated by subcloning SF3A3 (from human ORFeome 8.1 collection, 
Thermo Scientific) or SF3B3 (from Addgene, plasmid #11241) in the pLKO.1 CMV puro 
construct provided by A. Ittner (ETH Zürich), by using EcoRI and SalI (SF3A3) or EcoRI 
and MluI (SF3B3) restriction sites. As a control vector the empty pLKO.1 CMV puro 
construct was used. Since the wild-type coding sequence of Sf3b1 is toxic to bacteria, we 
used a codon optimized Sf3b1 to perform overexpression experiments (the DNA and amino 
acid sequence can be found in Supplementary Data 1). First, we amplified Sf3b1 from 
mouse cDNA until the internal XhoI restriction site (1–1,568 bp) and subcloned it into a 
pcDNA3 vector by using EcoRI/XhoI restriction sites. The synthesis and codon optimisation 
of the second part (1,578–3,915 bp) was performed by Genscript. Finally we subcloned the 
two parts of Sf3b1 by double ligation in a pcDNA3 vector by using EcoRI, XhoI and XbaI 
restriction sites.
Sf3b1 promoter-luciferase construct
1.5 kilobases (kb)of the Sf3b1 promoter was amplified from mouse BAC genomic DNA and 
cloned into the pGL3 luciferase reporter vector (Stratagene). HRE mutants of the respective 
promoters were generated by recombinant PCR37,38. Sense and antisense primers were 
generated bearing HRE mutations, which were used to amplify the mutant 5′ and 3′ regions 
of the promoter, respectively. The 5′ and 3′ products generated from the respective PCR 
reactions were pooled afterwards at a 1:1 ratio and re-amplified using primers targeting the 
5′ and 3′ ends of the respective promoters. To check for the correctness of the HRE mutation 
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in the right direction, HRE mutants of the respective promoters were verified by sequencing 
(Microsynth).
shRNA knockdown of Khk-A and Khk-C
Khk-A- or Khk-C-specific shRNAs were designed using the Life Technologies BLOCK-iT 
RNAi Designer online tool (Life Technologies), searching for 21mer targets of either Khk-
A- or Khk-C-specific transcripts. shRNAs were automatically compared to the mouse 
database using BLAST. As a loop sequence, the TRC-library loop sequence TCTGAG was 
used. Per isoform, three different shRNAs were chosen as promising, according to the 
program’s algorithm and cloned into the pLKO.1 lentiviral vector. The presence of the 
shRNA was confirmed by sequencing (Microsynth). shRNAs were then tested in NMCs for 
knockdown efficiency and specificity for either Khk-A or Khk-C. After validation, shRNAs 
shKhk-A#3, referred as shKhk-A and shKhk-C#2, referred as shKhk-C were chosen for all 
experiments described. The sequences are as follows: shKhk-A, sense (5′–3′): 
CCGGGATGACCTCCGCC AACAT 
TCTCTCGAGAGAATGTTGGCGGAGGTCATCTTTTTG; shKhk-C, sense (5′–3′): 
CCGGGCTCTTGCTGCATCGTCAACACTCGAGTGTTGAC GATGCAGCAAGAGC 
TTTTTG.
TRC lentiviral shRNA constructs
For lentiviral shRNA mediated knockdown the following shRNAs from the TRC library 
were used in a pLKO.1 construct: Sf3b1 (shSf3b1#1, TRCN0000295293; shSf3b1#2, 
TRCN0000295294), Sf3a3 (shSf3a3#1, TRCN0000285834; shSf3a3#2, 
TRCN0000277028), Sf3b2 (shSf3b2#3, TRCN0000123811; shSf3b2#4, 
TRCN0000123812), Sf3b3 (shSf3b3#5, TRCN0000311577; shSf3b3#11 
TRCN0000109223), Glut5 (shGlut5#4, TRCN0000079392; shGlut5#, TRCN0000079388), 
Hif1α (shHif1α, TRCN0000232220), Khk (shKhk, TRCN0000416511). As a non-targeting 
shRNA construct the pLKO.1 vector SHC002 (Sigma) was used.
RNA-isolation and reverse transcription
RNA was isolated with the RNeasy Mini Kit (Qiagen) and reverse-transcribed using a 
EcoDry Premix (OligoDT) (Clontech) according to the manufacturer’s instructions. 
Quantitative real-time PCR (qRT–PCR) reactions were prepared with Roche LightCycler 
480 SYBR Green I Master as recommended by the manufacturer and run on a LightCycler 
480 (Roche). Ct values were normalized to the housekeeping gene Hprt1. Primer sequence 
of qRT–PCR primers used in this study are as follows. Mouse: Hprt1 5′-
GGGGCTGTACTGCTTAACCAG-3′ and 5′-TGC TCATCAGTTGCCACTTC-3′; Sf3b1 
(primer pair A in Extended Data Fig. 3a) 5′-GCATCGTCCTCCAAAGATTGC-3′ and 5′-
GCATTCATTTTAGGATCG GGAGT-3′; Sf3b1 (primer pair B in Extended Data Fig. 3a) 
5′-CTCATGG GCTGTGCTATCTTGC-3′ and 5′-GTTGCTGCCTCAGCCAAAGC-3′; 
Sf3b1 (codon optimized, primer pair C in Extended Data Fig. 3a) 5′-CGTTAAA 
GGCCATCGTGAACG-3′ and 5′-CAATTTTCCTGCACTTTCTCATGC-3′; Sf3a3 5′-
GAACGGCTTATGGATGTTATGGC-3′ and 5′-GGTGATCGGAA TTGATCTGGTC-3′; 
Sf3b2 5′-CATCCCGAACCTCCCAAAGG-3′ and 5′-GC TCCT 
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ATCTCTGCCAATCTGG-3′; Sf3b3 5′-ATTTTGGAGTTACTACGCCC AG-3′ and 5′-
GCCATAAGTGACCGGATAACAC-3′; Khk-A 5′-CCAACATT CTGTGGACTTACG-3′ 
and 5′-CCTTCTCAAAGTCCTTAGCAG-3′; Khk-C 5′-GCTGACTTCAGGCAGAGG-3′ 
and 5′-CCTTCTCAAAGTCC TTAGC AG-3′; Glut-1 5′-
CAGTTCGGCTATAACACTGGTG-3′ and 5′-GCCCCCGAC AGAGAAGAT-3′; Pdk1 5′-
GGACTTCGGGTCAGTGAATGC-3′ and 5′-CGC AGAAACATAAACGAGGTC-3′; 
Pkm2 5′-CGCCTGGACATTGACTCTG-3′ and 5′-GAAATTCAGCCGAGCCACATT-3′; 
Glut5 5′-CCAATATGGGTACA ACGTAGCTG-3′ and 5′-
CCAATATGGGTACAACGTAGCTG-3′; sk.α-Actin 5′-
TATGTGGCTATCCAGGCGGTG-3′ and 5′-CCCAGAATCCAACACGAT GC-3′; Nppa 
5′-GTGCGGTGTCCAA CACAGAT-3′ and 5′-TCCAATCCTGTC AATCCTACCC-3′; 
Nppb 5′-AGTCCTTCG GTCTCAAGGCA-3′ and 5′-CCG ATCCGGTCTATCTTGTGC-3′; 
αMhc 5′-GCCCAGTACCTCCGAAAGTC-3′ and 5′-GCCTTAACATACTCCTTGTC-3′; 
βMhc 5′-GCATTCTCCTGCTGTT TCCTT-3′ and 5′-
TGGATTCTCAAACGTGTCTAGTGA-3′; human: HPRT1 5′-
CCTGGCGTCGTGATTAGTGAT-3′ and 5′-AGACGTTCAGTCCTGTCC ATAA-3′; 
SF3B1 5′-GTGGGCCTCGATTCTACAGG-3′ and 5′-GATGTCAC 
GTATCCAGCAAATCT-3′; KHK-A 5′-GCTATTCTGTGGACCTACGCT-3′ and 5′-
CAATGTGGATCCACTTGAACTG-3′ and KHK-C 5′-CTCCTGCT GCATCATCAAC-3′ 
and 5′-CAATGTGGATCCACTTGAACTG-3′; GLUT1 5′-
GGCCAAGAGTGTGCTAAAGAA-3′ and 5′-ACAGCGTTGATGCCAGA CAG-3′; PDK1 
5′-CTGTGATACGGATCAGAAACCG-3′ and 5′-TCCACCAA 
ACAATAAAGAGTGCT-3′; GLUT5 5′-TCCAGTATGGGTACAACGTGG-3′ and 5′-
CATGGACACGGTTACAGACCA-3′; AKR1B1 5′-TTTTCCCATTGG ATGAGTCGG-3′ 
and 5′-CCTGGAGATGGTTGAAGTTGG-3′; NPPA 5′-CA 
ACGCAGACCTGATGGATTT-3′ and 5′-AGCCCCCGCTTCTTCATTC-3′; NPPB 5′-
TGGAAACGTCCGGGTTACAG-3′ and 5′-CTGATCCGGTCCAT CTTCCT-3′; αMHC 5′-
GCCCTTTGACATTCGCACTG-3′ and 5′-CGGGA CAAAATCTTGGCTTTGA-3′; βMHC 
5′-ACTGCCGAGACCGAGTATG-3′ and 5′-GCGATCCTTGAGGTTGTAGAGC-3′.
Splice-junction microarrays
Total RNA was isolated from NMCs infected with shNs and shHif1α lentiviruses and 
cultured in either 21% or 3% O2.. In another experiment NMCs were transduced with shNs 
and shSf3b1 lentiviruses and cultured at 3% O2 before RNA was isolated. Complementary 
DNA samples were prepared using the GeneChip WT cDNA Synthesis and Amplification 
Kit (Affymetrix). cDNA was hybridized to AltSplice splice-junction microarrays and 
resulting data were analysed with version 3 of ASPIRE software as previously described39. 
The unprocessed cel files with microarray data are available from ArrayExpress with 
accession numbers E-MTAB-2652 and E-MTAB-3203, respectively.
Luciferase assays
The luciferase assay was performed from material of NMCs using a luciferase kit (Promega) 
as recommended by the manufacturer and analysed on the MicroLumatPlus LB 96V 
(Berthold Technologies).
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Chromatin and RNA immunoprecipitations
ChIP assays were performed with material from NMCs and the assays carried out using the 
ChIP-IT Kit (Active Motif) according to the manufacturer’s instructions. ChIP was 
performed with a ChIP-grade antibody from Abcam. In silico promoter analyses were 
performed using MatInspector and DiAlignTF (Genomatix). Sequences of primers used are 
5′-TTTCGCTGGCTTTTTAAGGA-3′ and 5′-ATCTTCGCCATTTTGTCCAC-3′.
RNA immunoprecipitation assays were performed with material from NMCs using a RNA-
ChIP-IT kit from Active Motif as recommended by the manufacturer. RNA 
immunoprecipitation was performed using a Sf3b1 antibody from MBL International. 
Sequences of primers used to detect potential binding of Sf3b1 on the branch points of Khk-
A and Khk-C are the following: branch point primer for Khk-A, 5′- 
CTACTTCCCTCTGCTCAGCC-3′ and 5′-GGTCATCC AGGACAAAATGC-3′; branch 
point primer for Khk-C, 5′-GGACCCTTC TTCTCTGAGGC-3′ and 5′-
CACTTGAGACACATCCACGC-3′.
Immunoblotting
Dissected hearts and NMCs lysates were homogenized by freeze slamming and solubilized 
in a modified SDS sample buffer sonicated and boiled for 5 min40). Protein lysates were 
resolved on 8%, 10% or 15% polyacrylamide minigels (BioRad) and transferred onto 
nitrocellulose membrane (GE Healthcare) by wet or semi-dry transfer. The following 
antibodies were used for immunoblotting rabbit HIF1α (catalogue no. NB-100-47; Novus 
Biologicals), a rabbit SF3B1 (catalogue no. ab172634; Abcam), a rabbit-KHK (catalogue 
no. HPA007040; Sigma), a rabbit KHK-C (custom made by Eurogentec) a rabbit Cre 
(catalogue no. 69050; Novagen), a rabbit SF3A3 (catalogue no. ab140605), a mouse SF3B2 
(catalogue no. ab56800), a rabbit SF3B3 (catalogue no. NBP2-20258) mouse α-actinin 
(catalogue no. A7811; Sigma) and a chicken-GFP (catalogue no. GFP-1020; Aves Labs). 
Immunodetection and visualization of signals by chemiluminescence was carried out as 
described40, or by using the ImageQuant LAS 4000 mini (GE Healthcare). Immunoblots for 
Khk-A/C and Khk-C were visualized using SuperSignal West Pico Chemiluminescent 
Substrate (Thermo Scientific).
Ketohexokinase splicing assay I
This Khk splicing assay including amplification of part of the Khk cDNA and the identified 
alternative spliced region was adapted from a splice assay for PKM1/M2 isoforms23. RNA 
isolated from NMCs transduced with shNs or shSf3b1 lentiviruses after treatment with 
isoproterenol or HIF1αΔODD and RNA isolated from sham- or 1K1C-treated wild-type left 
ventricles was reverse-transcribed then amplified using a forward primer (5′-
GAAGCAGATCCTGTGCGTG-3′) that bound to shared Khk A/C exon 1 and a reverse 
primer (5′-ATTGTGCTCCTCTATCCGC-3′) that bound to shared Khk A/C exon 5 
sequences. The 468-bp PCR products representing both Khk-A and Khk-C transcripts were 
then digested with HincII and run on a 1.5% agarose gel, after which the 468 bp (uncut Khk-
A-specific amplicon), 294 bp and 174 bp (HincII-cleaved Khk-C-specific amplicon) products 
were quantitated using ImageJ software.
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Ketohexokinase splicing assay II
To analyse KHK isoforms in human and mouse hearts or NMCs RT–PCR was performed. 
Total RNA was isolated from hearts or NMCs and reverse-transcribed into cDNA using the 
RNA to cDNA EcoDry Premix (OligoDT) kit (Clontech). Full length KHK-A/C cDNA was 
amplified by RT–PCR, loaded onto an agarose gel and purified by gel extraction. One 
hundred nanograms of full-length KHK-A/C cDNA was used as a template to amplify KHK-
A and KHK-C specific fragments, respectively, using primer pairs consisting of a common 
KHK A/C forward and KHK-A- or KHK-C-specific reverse primer set. To be able to 
distinguish between KHK-A and KHK-C isoforms, the corresponding amplicons differed in 
length. The influence of fragment length on fragment amplification was minimised by 
designing two sets of primer pairs for each isoform (primer set 1 vs primer set 2): Khk-A1 < 
Khk-C1 and Khk-A2 > Khk-C2. The primer sequences are the following: primer pair 1 
(human): KHK-A/C 5′-GAGAAGCAGATCCTGTGC-3′, KHK-A 5′-AGCGTAGGTCC 
ACAGAATAGC-3′ and KHK-C 5′-GGAGTTGTTGATGATGCAGC-3′; primer pair 2 
(human): KHK-A 5′-GCTATTCTGTGGACCTACGCT-3′ and KHK-C 5′-
CAGTTCAAGTGGATCCACATTG-3′; KHK-A/C 5′-GGTGTTGT GTGCGTCTATCC-3′; 
primer pair 1 (mouse); Khk-A/C 5′-GAAGCAGATC CTGTGCGTG-3′, Khk-A 5′-
GGTCTGAAGGACCACATATCG-3′ and Khk-C 5′-CATTGGAGTTGTTGACGATGC-3′; 
primer pair 2 (mouse): Khk-A 5′-CAT TCTGTGGACTTACGATATGTG-3′ and Khk-C 5′-
GTACCATTATACTCT ACGACACGAAC-3′; Khk-A/C 5′-
GGTGTTGTGTGCGTCTATCC-3′.
Ketohexokinase activity assay
The ketohexokinase activity assay41 was modified by adding Roche Complete Protease 
Inhibitor Cocktail and Roche PhosSTOP to the reaction mixture, addition of 140 μg NMCs 
protein per reaction and incubating for 2 h at 37 °C. Spectrophotometric absorbance 
measurements of the remaining fructose were performed in 96-well plates at 515 nm using a 
Spectra MAX 190 plate reader (Molecular Devices). Wild-type liver protein was used as a 
positive control and reactions without protein were used as negative controls.
Metabolomics
4 × 105 NMCs were cultured per 3-cm dish. Cells were washed with PBS and whole-cell 
culture plates were snap frozen on dry ice. Metabolites were extracted twice from plates 
with hot (75 °C) 70% ethanol. Targeted analysis of hexose-phosphates levels and of 
their 13C-labelling pattern was performed by ion-pairing, reverse phase, ultra-performance 
liquid chromatography–tandem mass spectrometry on a Thermo Quantum Ultra instrument 
(Thermo Scientific)42. Technical quadruplicates were merged using their mean.
Untargeted analysis of metabolites was performed by flow injection–time-of-flight mass 
spectrometry on a Agilent 6550 Instrument in negative mode 4 GHz, high resolution in a m/z 
range of 50–1,000 as reported earlier43. Ions were annotated to ionic derivatives of the 
metabolites listed in the KEGG database (organism hsa) using 0.001 atomic mass units 
(a.m.u.) tolerance. Data processing and analysis was done with Matlab.
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Immunofluorescent stainings
Immunofluorescent stainings were performed as described previously10. Cells were 
permeabilized and incubated with sarcomeric α-actinin antibody (Sigma) diluted 1:500 in 
2% horse serum, 0.025% TritonX-100/PBS overnight at 4 °C. Cells were washed with PBS 
and incubated with 4′,6-diamidino-2-phenylindole (DAPI), Phalloidin and AlexaFluor488 
anti-mouse secondary antibody for 1 h at room temperature. Afterwards, stainings were 
washed and mounted in Lisbeth medium.
[3H]leucine incorporation assay
Cardiomyocyte hypertrophy was evaluated by measuring [3H]leucine incorporation into 
newly synthesized proteins44. Cells were counted in a Neubauer chamber after trypsinization 
and scintillation counts were normalized to absolute cell number.
Ex vivo [3H]fructose/[14C](deoxy)-glucose uptake
Animals were euthanized 8 weeks after surgery and hearts were shortly placed into 1 M KCl 
solution. The left ventricle were cut into equal tissue pieces, dried on tissue, weighted and 
placed into 6-well plates with 2 ml medium (serum-free DMEM, 5 mM glucose and 8 μM 
fructose). Tissue explants were incubated in the same medium containing 1 mCi ml−1 
[3H]fructose (specific activity 5 Ci mmol−1) and 0.1 mCi ml−1 [14C]deoxy-D-glucose 
(specific activity 58 mCi mmol−1) and harvested at respective time points. Harvested 
explants were washed two times with PBS and dissolved in 0.5 ml 1 M KOH (70 °C, 10 
min, shaking). 5 ml scintillation liquid was added and radioactivity was measured in a 
Beckman LS6500 scintillation counter. The radioactivity counts were normalized to tissue 
weight.
In vivo [3H]fructose/[14C](deoxy)-glucose uptake and biodistribution
A mixture of 20 μl 1 mCi ml−1 [3H]fructose (specific activity 5 Ci mmol−1) and 200 μl 0.1 
mCi ml−1 [14C]deoxy-D-glucose (specific activity 55 mCi mmol−1) was applied to sham- or 
TAC-treated C57/Bl6 J mice at 3 weeks post operation by oral gavage. After 45 min animals 
were weighed and euthanized. Denoted organs were collected and weighed. Tissue was 
digested with 4 M ethanolic KOH, radioactivity was measured in a Beckman LS6500 
scintillation counter (Beckman) and calculated as disintegrations per minute (d.p.m.) per mg 
tissue weight.
Fructose content
Heart fructose content was measured using the fructose colorimetric/fluorometric assays kit 
according manufacturer’s instructions (Biovision) and as described previously45. Values 
were normalized to protein content.
[3H]fructose incorporation into RNA, DNA and protein
4 × 105 NMCs were seeded in 3-cm dishes and transduced in quadruplicates. On day 3, 
NMCs were incubated in maintenance medium containing 5 mM glucose, 8 μM unlabelled 
Fructose and 1 mCi ml−1 [3H]fructose (specific activity 5 Ci mmol−1) overnight. NMCs 
were washed three times with PBS before cell lysis was performed with 0.7 ml TRIzol 
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(Invitrogen). Fractionation into RNA, DNA and protein was performed according to the 
manufacturer’s instructions with adaptations of the volumes according to the starting 
volume.
ADP/ATP Assay
5 × 104 NMCs were cultured in a 96-well format and treated as denoted. After 3 days in 
culture NMCs were analysed using a Bioassay Systems Enzylight ATP:ADP ratio kit 
(ELDT-100, Bioassay Systems) according to manufacturer’s instructions. Cellular ATP 
from 10 μl of lysate reacted with D-luciferin to generate a light signal that was proportional 
to the intracellular ATP concentration. In a second step, ADP was converted to ATP by an 
enzymatic reaction, and reacting with D-luciferin as in the first step. Luminometry was 
analysed using a MicroLumatPlus LB 96V (Berthold Technologies).
Myocardial ATP content
The level of myocardial ATP was measured by using a colorimetric/fluorometric assay kit 
(Abcam) according to the manufacturer’s instructions. Left-ventricular samples of about 10 
mg weight were used as a starting material. The absorbance was read at 550 nm using a 
Tecan Infinite M1000 Pro plate reader and ATP content was calculated based on a standard 
curve generated from ATP-standards on the same 96-well plate. Values were normalized to 
protein concentrations obtained from Bradford assays.
[3H]fructose incorporation into lipids
4 × 105 cells were seeded in 3-cm dishes and transduced in quadruplicates. On day 3, cells 
were loaded with 0.25 mM oleic acid overnight and 1 μCi ml−1 [3H]fructose (specific 
activity 5.0 Ci mmol−1) was added to the medium. On day 4, cells were washed twice with 
PBS and lipids were extracted by hexane-isopropanol extraction46. Protein concentration 
was measured by BCA protein assay and radioactivity count was normalized to protein 
content.
Oil Red O staining
Oil Red O staining was combined with immunofluorescence according to a protocol in ref. 
47. Spot-detection was performed with the Anchor image analysis platform (http://
www.microscopyimages.org/). Nuclei are segmented by first thresholding the (Gaussian-
blurred) DAPI channel with Otsu’s method, and then a watershed segmentation on the 
inverted Euclidian distance transform. Neighbouring segments are merged to increase an 
ellipticity score. A merge occurs if: ell(xy) > 0.5[ ell(x) + ell(y)], where xy is the merge of 
segments x and y. Segments with an area >50 μm2 are deemed nuclei. Cells are segmented 
by thresholding the histogram-stretched FITC channel, combining with the nuclei binary-
image, and performing ultimate erosion using the segmented nuclei as seeds. Spots are 
segmented by first performing rolling-ball background correction, thresholding, and then a 
watershed segmentation on the inverted intensity after median filtering. Segments with an 
area >0.2 μm2 and a minimum gradient signal are deemed spots.
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Nile red staining
4 × 105 NMCs were incubated with 0.25 mM oleic acid (Sigma-Aldrich) overnight and 
stained with 10 μg ml−1 Nile red (Sigma-Aldrich) for 10 min in PBS48. Values were 
normalized to cell number.
Cell size quantification
NMCs were stained after 3 days of culturing for sarcomeric α-actinin (1:500, Sigma), 
phalloidin and DAPI. Pictures of all channels were taken using a 20× magnification. Using 
the software Cell Profiler, sarcomeric α-actinin-positive cells were identified and cell area 
was quantified. Multi-nucleated cells were counted manually and average area per cell was 
corrected taking into account the number of multi-nucleated cells.
Measurements of extracellular acidification and oxygen consumption rate
1 × 105 NMCs per well were seeded in a 24-well Seahorse cell culture plate (SeaHorse 
Bioscience) and assayed at day 3. ECAR and OCR were measured in parallel using a 
SeaHorse XF24 Flux Analyzer (SeaHorse Bioscience) in NMCs incubated in low-buffered 
Krebs-Henseleit buffer, supplemented with glucose (5 mM) and fructose (25 μM). After five 
consecutive basal measurements of ECAR to measure glycolysis related lactate production, 
0.25 mM oleic acid was added and oxygen consumption rates were measured again for five 
consecutive times. Finally, 1 μM carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone 
was injected to stimulate maximal OCR in NMCs, reflecting mitochondrial reserve capacity.
Statistical analysis
For statistical analyses, unpaired, two-tailed Student’s t-tests (Excel) or one-way ANOVA 
analyses followed by a Dunnet’s multiple comparison post-test were used as indicated in the 
respective figure legends. No statistical methods were used to predetermine sample size.
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Extended Data
Extended Data Figure 1. HIF1α induces SF3B1 gene expression that mediates KHK-C isoform 
expression
a, Schematic experimental workflow. b, Comparison of C1QBP, HNRNPH3, JMJD6 and 
SF3B1 promoter sequences of human and mouse illustrate putative HREs up to 1,000 bp 
upstream of the transcription start site (TSS). The core consensus HRE motif is shown in 
colour. c, d, qPCR (c) and immunoblotting (d) for Sf3b1 expression in NMCs transduced 
with scrambled shNs viruses or viruses bearing two distinct shRNAs against Sf3b1. All 
values obtained by qPCR are presented in relation to Sf3b1 expression in shNs (set as 1.0) (n 
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= 3 biological replicates per group). e, RT–PCR analysis of Khk mRNA as in Fig. 1 g in 
NMCs transduced as indicated. f, RT–PCR analyses of Khk mRNA from NMCs infected as 
indicated and stimulated with mock or isoproterenol (ISO). PCR products were digested 
with HincII as in Fig. 1c . Splicing is quantified as percent of the Khk-C isoform (%Khk-C). 
g, RT–PCR based assessment of Khk-A and Khk-C isoform expression as done in Fig. 1 g. h, 
i, Ventricular samples of sham- or 1K1C-operated mice were analysed for Khk isoform 
expression (h) as done in Fig. 1 g or Sf3b1, Khk-A and Khk-C mRNA expression (i) by 
qPCR; n = 6 for each group. j, k, Ventricular samples of sham- or TAC-treated mice (j) and 
NaCl- or isoproterenol-treated mice (k) were analysed for expression of Sf3b1, Khk-A and 
Khk-C mRNA expression by qPCR (n = 6 for each individual group). l, NMCs transduced as 
specified were validated for protein expression of indicated proteins by using immunoblots. 
In addition lysates of NMCs overexpressing KHK-A or KHK-C were processed for 
immunoblotting Khk antibodies. m, n, Ventricular samples of sham- or TAC-treated (m) 
and sham- or isoproterenol-treated mice (n) were analysed for indicated proteins by 
immunoblotting. o, Probes from left ventricles of 1K1C-, TAC- or isoproterenol-treated 
mice and their corresponding controls were analysed for mRNA expression of Hif1α targets. 
All values were presented in relation to sham-operated controls set as 1.0 (n = 6 for each 
individual group). p, q, Left-ventricular biopsies of HCM patients and healthy controls were 
analysed for mRNA expression of SF3B1, KHK-A and KHK-C (p) and HIF1α targets (q). 
All values are presented in relation to healthy controls set as 1.0 (n = 6 for controls and n = 
16 for patient samples). Error bars are s.d. (c) or s.e.m. (i–k, o–q). *P < 0.05; **P < 0.01; 
***P < 0.001; two-tailed unpaired t-test (c, i–k, o–q).
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Extended Data Figure 2. SF3B1 is a HIF1α-target gene, whose product regulates growth and 
metabolic shift in vitro
a, NMCs infected as denoted, were stimulated with either mock, phenylephrine and 
isoproterenol, respectively. Sf3b1 mRNA expression was examined by qPCR. (n = 3 
biological replicates). b, NMCs were transduced as indicated and processed for qPCR 
analysis of Sf3b1 mRNA. (n = 3 biological replicates). c, Comparative analysis of a 
conserved HRE (shown in red) in the promoter of SF3B1 of diverse mammalian species 
located 122 bp downstream of the transcription start site (TSS). d–g, Immunoblot detection 
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of indicated proteins of NMCs transduced with shNs, and shSf3b lentiviruses treated with 
phenylephrine or isoproterenol (d) co-infected with empty vector or HIF1αΔODD (e) 
cultured under normoxic (21% O2) or hypoxic (3% O2) conditions (f) and co-transduced 
with shVhl lentiviruses (g). h–o, Evaluation of [3H]leucine incorporation and the myosin 
heavy chain α/β mRNA expression ratio in NMCs treated with either phenylephrine or 
isoproterenol (h, l), HIF1αΔODD overexpression (i, m), hypoxia (j, n) or pVhl deletion (k, 
o), with or without shSf3b1 mediated Sf3b1 depletion. Obtained values are shown relative to 
incorporated radioactivity in control (shNS) NMCs (set as 1.0) (n = 4 per individual group). 
p, NMCs treated as in i were microscopically analysed for cell size using CellProfiler. Data 
represents 1 of 3 independent experiments with approximately 200 analysed cells per 
experiment. q, Lysates of NMCs treated as indicated, were assessed for protein expression 
of specified proteins by immunoblots. r, Evaluation of [3H]leucine incorporation of NMCs 
infected as indicated. Obtained values are shown relative to incorporated radioactivity in 
control (shNs/empty) NMCs (set as 1.0) (n = 3 per individual group). s–z, Assessment of 
extracellular acidification rate (ECAR), and oleic acid- and carbonyl cyanide-4-
(trifluoromethoxy)phenylhydrazone (FCCP)-induced oxygen consumption rate (OCR) in 
NMCs transduced and treated as indicated. Highlighted ECAR measurements were done at 
baseline. All data are compared to shNs-transduced NMCs. (n = 8 biological replicates in 
the group shNs + isoproterenol; n = 10 biological replicates in all other groups). Error bars 
are s.d. (a, b, h–o, r) or s.e.m. (p, s–z). *P < 0.05; **P < 0.01; ***P < 0.001. Two-tailed 
unpaired t-test (b, t, u, w–z). One-way ANOVA followed by Dunnett’s multiple comparison 
post-test (a, h–p, r).
Mirtschink et al. Page 22
Nature. Author manuscript; available in PMC 2016 March 09.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Extended Data Figure 3. Influence of U2snRNP-complex members on KHK isoform expression 
and validation of KHK-C-mediated fructose uptake and metabolism
a, NMCs were transduced with either shNs or shSf3b1 and transfected with codon optimized 
Sf3b1 or empty construct and expression of denoted proteins was assessed. b, NMCs were 
transduced with either shNs or shSf3b1 and transfected with codon-optimized Sf3b1 or 
empty construct, respectively. Exogenous Sf3b1-expression was evaluated by qRT–PCR. 
Three different primer pairs were used. Primer pair A detects both endogenous and 
exogenous codon-optimized Sf3b1 (top). Primer pair B recognizes Sf3b1 close to the 
shRNA binding site and is specific for endogenous Sf3b1 (left). Primer pair C is located in 
the codon-optimized region (right). Values were normalized to shNs/empty-vector-infected 
NMCs (n = 3 biological replicates per group). c, [3H]leucine incorporation normalized to 
cell number in NMCs treated as in b (n = 4 biological replicates per group). d, NMCs 
transduced with empty vector or human SF3A3 or SF3B3 were assessed for mRNA 
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expression of Khk-A and Khk-C by qRT–PCR. Values were normalized to empty-vector-
transduced NMCs (n = 3 biological replicates per group). e, NMCs transduced as in d were 
immunoblotted for indicated proteins. f, NMCs transduced as indicated were probed for 
mRNA expression of Khk-A or Khk-C by qRT–PCR. Values were normalized to shNs/
empty-vector-transduced NMCs (n = 3 biological replicates). g, NMCs treated with either 
scrambled shRNA or two different shRNAs targeting either Sf3a3, Sf3b2 or Sf3b3 were co-
transduced with empty vector or HIF1αΔODD. Protein expression of Khk-A/C or Khk-C 
specifically was evaluated by immunoblotting. h, Evaluation of [3H]leucine incorporation of 
NMCs infected as in d normalized to empty-vector-transduced NMCs (n = 4 biological 
replicates per group). i, Lysates of NMCs treated as indicated were immunoblotted for 
specified proteins. j, KHK-activity in lysates of NMCs transduced with a combination of 
lentiviruses expressing either shKhk targeting mouse Khk and human KHK-A or shKhk and 
human KHK-C or a scrambled shRNA control together with an empty vector. k, Evaluation 
of the kinetics of [13C]fructose-1-phosphate accumulation in NMCs treated as in i at the 
respective time points (n = 3 biological replicates). l, Glut5 mRNA expression in NMCs 
transduced as indicated. (n = 3 biological replicates per group). m, NMCs transduced as 
indicated were microscopically analysed for cell size. Data represents 1 of 3 experiments 
with approximately 50 analysed cells per experiment n, Khk-A- and Khk-C-specific 
shRNAs were evaluated for their potential to inhibit Khk-A and Khk-C isoform expression, 
respectively. NMCs were infected with shNs, shKhk-A or shKhk-C lentiviruses. Data are 
shown in relation to shNs NMCs (set to 1.0) (n = 3 biological replicates). Error bars are s.d. 
(b–d, f, h, k, l, n) or s.e.m. (m). *P < 0.05; **P < 0.01; ***P < 0.001. One-way ANOVA 
followed by Dunnett’s multiple comparison post-test (b–d, f, k, l, m, n).
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Extended Data Figure 4. Downstream metabolic effects of fructose metabolism in NMCs
a, log2 fold change of metabolites in NMCs overexpressing KHK-C and cultured with 
glucose or glucose and fructose compared to the corresponding control transduced NMCs (n 
= 4 biological replicates per group). b, Incorporation of [3H]fructose into RNA (top), DNA 
(middle) and protein (bottom) of NMCs treated as indicated (n = 4 biological replicates per 
group). c, Uptake of [14C]deoxyglucose in NMCs infected as in b at depicted time points (n 
= 4 biological replicates per group). d, [3H]leucine incorporation in NMCs transduced with 
shNs or shKhk and co-transduced with either empty overexpression vector or KHK-A or 
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KHK-C respectively. NMCs were cultured in media with increasing fructose concentrations, 
under physiologic glucose amounts or with increasing glucose concentrations under 
physiologic fructose amounts. Data are presented relative to shNs/empty-vector-transduced 
NMCs at 5 mM glucose/0 μM fructose (n = 4 biological replicates). e, ADP/ATP ratios in 
NMCs transduced as indicated. (n = 4 biological replicates, data show 1 of 3 representative 
experiments). f, Immunofluorescence images of NMCs transduced with empty vector (upper 
panel) or HIF1αΔODD (middle panel) lentiviruses or exposed to hypoxia (lower panel) 
were additionally transduced as indicated. Prior to staining for sarcomeric α-actinin, Oil Red 
O and DAPI, NMCs were incubated with oleic acid. g, Quantification of lipid droplets/cell 
in NMCs of immunofluorescent images shown in f. h, Ratio of lipid droplets/cell area of 
NMCs shown in g. i–l, NMCs were infected as indicated and processed for oxygen 
consumption rate (OCR) and extracellular acidification rate (ECAR) measurements under 
basal conditions or after injection of OA or FCCP. Depicted are rates expressed as OCR to 
ECAR ratios (upper panels) or individual ECAR (for measurements at baseline) or OCR 
values (n = 8 biological replicates for HIF1αΔODD/shKhk-A; n = 10 biological replicates 
for all other groups). Error bars are s.d. (b–e) or s.e.m. (g–l). *P < 0.05; **P < 0.01; ***P < 
0.001. One-way ANOVA followed by Dunnett’s multiple comparison post-test (b–e, g, h). 
Two-tailed unpaired t-test (i–l).
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Extended Data Figure 5. Fructose and glucose uptake ex vivo and validation of AAV9-fl/fl-
shSf3b1 viruses
a, Ratio of left-ventricular weight to body weight of sham- or TAC-treated C57/Bl6J mice; 
(n = 7 per group). b, c, [3H]fructose (b) and [14C]deoxy-glucose (c) were co-applied by oral 
gavage and biodistribution was measured at 45 min post injection (n = 7 per group). d, Ratio 
of left-ventricular weight to tibia length (LV/TL) of sham- or 1K1C-treated C57/Bl6J wild-
type mice (n = 6 for sham and n = 7 for 1K1C-treated mice). e, Fructose levels in probes 
from left ventricles of indicated mice as determined by a quantitative colorimetric assay, 
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normalized to protein amount (n = 4 for sham and n = 5 for hearts of 1K1C-treated mice). f, 
g, Freshly isolated left-ventricular pieces of sham- or 1K1C-treated mice incubated in 
medium containing either [14C]fructose (f) or [14C]deoxyglucose (g) as indicated were 
processed for uptake measurements. Counts were normalized to tissue weight (n = 6 per 
time point and treatment). h–j, qPCR analyses of Glut5 mRNA expression in left ventricles 
of 1K1C- (h), TAC- (i) or isoproterenol-treated (j) mice. All values are presented in relation 
to Glut5 expression in shams (set as 1.0). n = 5 for sham-treated mice as controls for TAC-
treated mice (n = 6), all other groups n = 7. k, l, Relative mRNA expression of GLUT5 and 
aldose reductase (AKR1B1) in left-ventricular biopsies of patients diagnosed with aortic 
stenosis (k) or HCM (l) in relation to healthy controls (set as 1.0) was analysed by qPCR (n 
= 6 for controls; n = 16 for HCM and n = 17 for patients with aortic stenosis). m, Integration 
of AAV9-fl/fl-shSf3b1#1 viruses in the myocardium of Mlc2-cre− or Mlc2v-cre+ mice was 
examined 12 weeks after intravenous injection by confocal microscopy (using 20× 
magnification) of left-ventricular cryoslices stained against GFP and sarcomeric α-actinin 
and counterstained for DAPI. n, Ventricular samples of Mlc2v-cre− or Mlc2-cre+ mice 
transduced with AAV9-fl/fl-shSf3b1#1 or AAV9-fl/fl-shSf3b1#2 viruses were assessed for 
expression of indicated proteins by immunoblotting. o, p, Ratio of left-ventricular weight to 
tibia length (o) and ejection fraction (%EF) (p) of sham- or TAC-treated Mlc2v-cre− and 
Mlc2v-cre+ mice injected with AAV9-fl/fl-shSf3b1#1 (number of mice per group is given in 
Extended Data Table 1). q, Lysates of hearts from sham- or TAC-operated Mlc2v-cre− and 
Mlc2v-cre+ mice transduced with AAV9-fl/fl-shSf3b1#1 viruses were processed for 
immunoblotting with antibodies as denoted. Error bars are s.e.m. (a–l, o, p). *P < 0.05; **P 
< 0.01; ***P < 0.001, two-tailed unpaired t-test (a–l, o, p).
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Extended Data Figure 6. Pathologic growth is dependent on HIF1α-driven and SF3B1-mediated 
KHK-C expression
a–f, Ratio of left-ventricular weight to tibia length (LV/TL) (a), mRNA expression of the 
hypertrophic markers Nppa (b), myosin heavy chain β (βMhc) (c) and myosin heavy chain α 
(αMhc) (d), ejection fraction (%EF) (e) and left-ventricular ATP content (f) of sham- or 
TAC-treated Khk-A+/+ and Khk-A−/− mice. g–l, Ratio of left-ventricular weight to tibia 
length (LV/TL) (g), mRNA expression of the hypertrophic markers Nppa (h), myosin heavy 
chain β (βMhc) (i) and myosin heavy chain α (αMhc) (j), ejection fraction (%EF) (k) and 
left-ventricular ATP content (l) of Khk-A/C+/+ and Khk-A/C−/− mice. m, n, Lysates from 
ventricles of sham- or TAC-operated Khk-A+/+ and Khk-A−/− mice (m) and Khk-A/C+/+ and 
Khk-A/C−/− mice (n) were processed for immunoblotting with antibodies as indicated. o–t, 
Assessment of hypertrophic marker gene expression (Nppa, βMhc and αMhc) in ventricles 
of TAC- vs sham-treated Khk-A−/− mice and their corresponding Khk-A+/+ controls (o–q) as 
well as Khk-A/C−/− mice and their corresponding Khk-A/C+/+ controls (r–t). u, v, Mean 
blood pressure (BP) in mmHg of Khk-A+/+ and Khk-A−/− (u) as well as Khk-A/C+/+ and Khk-
A/C−/− mice (v) 8 weeks after sham or 1K1C treatment. For a–l, o–v, the number of mice 
per group is given in Extended Data Table 2. Error bars are s.e.m. *P < 0.05; **P < 0.01; 
***P < 0.001; two-tailed unpaired t-test.
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Extended Data Figure 7. Model explaining how HIF1α activation of SF3B1-dependent splicing of 
KHK regulates fructose and glucose metabolism to promote cardiac hypertrophy in response to 
pathologic stress
In this model, pathologic stress leads to increased expression of HIF1α and HIF1α-
dependent activation of genes encoding glycolytic enzymes and the splicing factor SF3B1. 
SF3B1, in turn, assembles at the branch-point sequence upstream of exon 3C of KHK pre-
mRNA leading to an inclusion of this exon and KHK-C protein production. This shift in 
isoform expression from KHK-A to KHK-C in response to HIF1α–SF3B1 pathway 
activation drives KHK-C-dependent fructose uptake via stimulation of GLUT5 expression, 
the conversion of fructose to fructose-1-phosphate (F1P) and contributes simultaneously to 
the activation of glucose uptake and metabolism through a yet-to-be-determined mechanism. 
The model holds that the unrestrained conversion of fructose to F1P by KHK-C limits ATP 
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levels, thereby alleviating potential allosteric inhibition of phosphofructokinase (PFK) by 
ATP to maintain a high glycolytic flux. F1P is further metabolized to dehydroxyacetone 
phosphate (DHAP) and glyceraldehyde (GA). While DHAP serves as a precursor for 
glycerol synthesis, GA can be further converted to glyceraldehyde-3-phosphate (G3P), a key 
glycolytic intermediate. G3P can be channelled into the non-oxidative pentose phosphate 
pathway (PPP) supporting nucleic and amino acid biosynthesis. This metabolic 
constellation, created by the activation of the HIF1α–SF3B1–KHK-C axis, increases 
macromolecular biosynthetic capacity essential for hypertrophic growth, steatosis and 
cardiac dysfunction. HKII and F-1,6-BP denotes hexokinase II and fructose-1,6-
bisphosphate, respectively.
Extended Data Table 1
Echocardiographic analysis of sham-, 1K1C- or TAC-
treated Mlc2v-cre−/-cre+ mice injected with AAV9-fl/fl-
shSf3b1 viruses.
Mlc2v-cre − Mlc2v-cre +
AAV9 fl/fl shSf3b1#1 AAV9 fl/fl shSf3b1#1
sham 1K1C sham 1K1C
n 4 3 5 3
BW (g) 27.5 ± 0.6 27.3 ± 0.7 27.3 ± 0.6 27.8 ± 0.8
IVS;d (mm) 0.71 ± 0.03 1.00 ± 0.03** 0.70 ± 0.02 0.80 ± 0.04
IVS;s (mm) 0.98 ± 0.02 1.30 ± 0.05** 1.04 ± 0.09 1.08 ± 0.08
LVID;d (mm) 3.97 ± 0.08 4.13 ± 0.10 3.85 ± 0.11 4.09 ± 0.10
LVID;s (mm) 3.08 ± 0.10 3.30 ± 0.11 2.86 ± 0.15 2.98 ± 0.18
LVPW;d (mm) 0.69 ± 0.01 0.85 ± 0.03** 0.67 ± 0.02 0.82 ± 0.01
LVPW;s (mm) 0.91 ± 0.35 1.08 ± 0.12 0.93 ± 0.09 0.97 ± 0.04
%FS 27.8 ± 1.9 25.3 ± 2.1 29.8 ± 1.6 27.1 ± 2.8
E/A 2.21 ± 0.26 0.80 ± 0.06*** 2.17 ± 0.17 1.73 ± 0.11
Mlc2v-cre − Mlc2v-cre +
AAV9 fl/fl shSf3b1#1 AAV9 fl/fl shSf3b1#1
sham TAC sham TAC
n 5 4 5 5
BW (g) 27.4 ± 0.8 28.0 ± 0.9 26.5 ± 0.5 26.9 ± 0.3
IVS;d (mm) 0.70 ± 0.03 0.98 ± 0.03*** 0.68 ± 0.02 0.84 ± 0.04
IVS;s (mm) 0.96 ± 0.06 1.37 ± 0.04** 0.97 ± 0.05 1.18 ± 0.05
LVID;d (mm) 3.94 ± 0.06 4.04 ± 0.09 3.82 ± 0.06 3.68 ± 0.06
LVID;s (mm) 2.89 ± 0.13 2.80 ± 0.09 2.71 ± 0.13 2.54 ± 0.11
LVPW;d (mm) 0.68 ± 0.02 0.98 ± 0.04*** 0.70 ± 0.02 0.82 ± 0.03
LVPW;s (mm) 0.97 ± 0.06 1.37 ± 0.10** 0.99 ± 0.07 1.11 ± 0.03
%FS 30.4 ± 2.3 19.9 ± 3.9* 30.04 ± 3.8 34.2 ± 1.3
E/A 1.62 ± 0.09 1.72 ± 0.23 1.68 ± 0.02 1.74 ± 0.12
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Mlc2v-cre − Mlc2v-cre +
AAV9 fl/fl shSf3b1#1 AAV9 fl/fl shSf3b1#1
sham 1K1C sham 1K1C
Aortic Vel. (mm/s) 923 ± 58 3920± 305*** 878 ±72 3670± 190***
Mlc2v-cre − Mlc2v-cre +
AAV9 fl/fl shSf3b1#2 AAV9 fl/fl shSf3b1#2
sham TAC sham TAC
n 5 4 5 5
BW (g) 27.4 ± 0.8 28.0 ± 0.9 26.5 ± 0.5 26.9 ± 0.3
IVS;d (mm) 0.70 ± 0.03 0.98 ± 0.03*** 0.68 ± 0.02 0.84 ± 0.04
IVS;s (mm) 0.96 ± 0.06 1.37 ± 0.04** 0.97 ± 0.05 1.18 ± 0.05
LVID;d (mm) 3.94 ± 0.06 4.04 ± 0.09 3.82 ± 0.06 3.68 ± 0.06
LVID;s (mm) 2.89 ± 0.13 2.80 ± 0.09 2.71 ± 0.13 2.54 ± 0.11
LVPW;d (mm) 0.68 ± 0.02 0.98 ± 0.04*** 0.70 ± 0.02 0.82 ± 0.03
LVPW;s (mm) 0.97 ± 0.06 1.37 ± 0.10** 0.99 ± 0.07 1.11 ± 0.03
%FS 30.4 ± 2.3 19.9 ± 3.9* 30.04 ± 3.8 34.2 ± 1.3
E/A 1.62 ± 0.09 1.72 ± 0.23 1.68 ± 0.02 1.74 ± 0.12
Aortic Vel. (mm/s) 923 ± 58 3920± 305*** 878 ±72 3670± 190***
BW, body weight; IVS;d, interventricular septum diameter in diastole, IVS;s, interventricular septum diameter in systole; 
LVID;d, left-ventricular inner diameter in diastole; LVID;s, left-ventricular inner diameter in systole; LVPW;d, left-
ventricular posterior wall diameter in diastole, LVPW;s, left-ventricular posterior wall diameter in systole; %FS, fractional 
shortening; E/A, ratio of early (E) to late (A) ventricular filling velocities; Aortic Vel. = aortic velocity. Values shown are 
mean ± s.e.m.;
*
P < 0.05;
**
P < 0.01;
***
P < 0.001; two-tailed unpaired t-test.
Extended Data Table 2
Echocardiographic analysis of sham- or TAC-operated 
Khk-A+/+/Khk-A−/− and Khk-A/C+/+/Khk-A/C−/− mice.
Khk-A+/+ Khk-A−/−
sham TAC sham TAC
n 6 6 5 6
BW (g) 25.6 ± 0.7 27.3 ± 0.8 25.4 ± 0.7 25.6 ± 0.7
IVS;d (mm) 0.73 ± 0.01 0.98 ± 0.02*** 0.72 ± 0.01 1.00 ± 0.03***
IVS;s (mm) 1.03 ± 0.07 1.34 ± 0.04** 1.12 ± 0.01 1.36 ± 0.06**
LVID;d (mm) 3.85 ± 0.08 3.80 ± 0.06 3.75 ± 0.10 3.73 ± 0.07
LVID;s (mm) 2.71 ± 0.16 2.65 ± 0.11 2.66 ± 0.20 2.70 ± 0.10
LVPW;d (mm) 0.72 ± 0.01 0.99 ± 0.04*** 0.72 ± 0.01 0.99 ± 0.03***
LVPW;s (mm) 1.04 ± 0.03 1.35 ± 0.03*** 1.05 ± 0.01 1.32 ± 0.05***
%FS 34.0 ±2.1 26.3 ±1.5* 34.3 ± 1.7 26.0 ± 1.2*
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Khk-A+/+ Khk-A−/−
sham TAC sham TAC
E/A 1.38 ± 0.11 2.20 ± 0.05** 1.97 ± 0.4 1.90 ± 0.4
Aortic Vel. (mm/s) 938 ± 55 4250± 275*** 880 ± 68 3700± 308***
Khk-A/C+/+ Khk-A/C−/−
sham TAC sham TAC
n 5 6 6 5
BW (g) 25.8 ± 0.6 24.9 ± 0.8 24.51 ± 0.6 24.4 ± 0.6
IVS;d (mm) 0.72 ± 0.01 1.00 ± 0.05** 0.64 ± 0.04 0.83 ± 0.06
IVS;s (mm) 1.15 ± 0.01 1.42 ± 0.07* 1.06 ± 0.07 1.19 ± 0.13
LVID;d (mm) 3.53 ± 0.13 3.70 ± 0.23 3.65 ± 0.13 3.67 ± 0.04
LVID;s (mm) 2.28 ± 0.27 2.61 ± 0.33 2.49 ± 0.17 2.45 ± 0.10
LVPW;d (mm) 0.69 ± 0.03 1.00 ± 0.05*** 0.67 ± 0.02 0.81 ± 0.04*
LVPW;s (mm) 1.12 ± 0.03 1.25 ± 0.03* 1.00 ± 0.06 1.11 ± 0.07
%FS 35.5 ± 3.0 27.5 ±1.6* 32.1 ± 2.30 33.4 ± 2.9
E/A 1.51 ± 0.09 1.56 ± 0.17 1.77 ± 0.10 1.64 ± 0.21
Aortic Vel. (mm/s) 928 ± 120 4020± 232*** 937 ± 59 3600± 292***
BW, body weight; IVS;d, interventricular septum diameter in diastole, IVS;s, interventricular septum diameter in systole; 
LVID;d, left-ventricular inner diameter in diastole; LVID;s, left-ventricular inner diameter in systole; LVPW;d, left-
ventricular posterior wall diameter in diastole, LVPW;s, left-ventricular posterior wall diameter in systole; %FS, fractional 
shortening; E/A, ratio of early (E) to late (A) ventricular filling velocities; Aortic Vel. = aortic velocity. Values shown are 
mean ± s.e.m.;
*
P < 0.05;
**
P < 0.01;
***
P < 0.001; two-tailed unpaired t-test.
Extended Data Table 3
Echocardiographic analysis of sham- or 1K1C-operated 
Khk-A+/+/Khk-A−/− and Khk-A/C+/+/Khk-A/C−/− mice.
Khk-A+/+ Khk-A−/−
sham 1K1C sham 1K1C
n 5 6 5 6
BW (g) 27.2 ± 0.7 27.1 ± 0.6 28.2 ± 2.0 29.7 ± 0.5
IVS;d (mm) 0.75 ± 0.01 0.94 ± 0.03*** 0.72 ± 0.02 1.01 ± 0.06**
IVS;s (mm) 1.08 ± 0.05 1.31 ± 0.05** 1.00 ± 0.04 1.31 ± 0.09*
LVID;d (mm) 4.02 ± 0.10 3.93 ± 0.12 3.91 ± 0.18 4.37 ± 0.32
LVID;s (mm) 3.02 ± 0.08 3.03 ± 0.14 2.90 ± 0.20 3.45 ± 0.40
LVPW;d (mm) 0.73 ± 0.02 0.99 ± 0.04*** 0.74 ± 0.02 0.97 ± 0.04**
LVPW;s (mm) 1.01 ± 0.05 1.30 ± 0.05** 1.06 ± 0.05 1.29 ± 0.06*
%FS 27.1 ± 1.5 22.6 ± 1.4* 28.8 ± 3.4 19.2 ± 3.05*
E/A 1.97 ± 0.17 1.47 ± 0.10* 1.83 ± 0.55 1.27 ± 0.14
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Khk-A+/+ Khk-A−/−
sham 1K1C sham 1K1C
Khk-A/C+/+ Khk-A/C−/−
sham 1K1C sham 1K1C
n 5 6 6 5
BW (g) 25.8 ± 0.6 24.9 ± 0.8 24.51 ± 0.6 24.4 ± 0.6
IVS;d (mm) 0.72 ± 0.01 1.00 ± 0.05** 0.64 ± 0.04 0.83 ± 0.06
IVS;s (mm) 1.15 ± 0.01 1.42 ± 0.07* 1.06 ± 0.07 1.19 ± 0.13
LVID;d (mm) 3.53 ± 0.13 3.70 ± 0.23 3.65 ± 0.13 3.67 ± 0.04
LVID;s (mm) 2.28 ± 0.27 2.61 ± 0.33 2.49 ± 0.17 2.45 ± 0.10
LVPW;d (mm) 0.69 ± 0.03 1.00 ± 0.05*** 0.67 ± 0.02 0.81 ± 0.04*
LVPW;s (mm) 1.12 ± 0.03 1.25 ± 0.03* 1.00 ± 0.06 1.11 ± 0.07
%FS 35.5 ± 3.0 27.5 ± 1.6* 32.1 ± 2.30 33.4 ± 2.9
E/A 1.51 ± 0.09 1.56 ± 0.17 1.77 ± 0.10 1.64 ± 0.21
BW, body weight; IVS;d, interventricular septum diameter in diastole, IVS;s, interventricular septum diameter in systole; 
LVID;d, left-ventricular inner diameter in diastole; LVID;s, left-ventricular inner diameter in systole; LVPW;d, left-
ventricular posterior wall diameter in diastole, LVPW;s, left-ventricular posterior wall diameter in systole; %FS, fractional 
shortening; E/A, ratio of early (E) to late (A) ventricular filling velocities; Aortic Vel. = aortic velocity. Values shown are 
mean ± s.e.m.;
*
P < 0.05;
**
P < 0.01;
***
P < 0.001; two-tailed unpaired t-test.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Identification of Hif1α-dependent splicing factors and splicing events
a, Expression of splice factors in NMCs transduced and cultured as indicated versus NMCs 
treated with non-silencing shRNA (shNs) and cultured at 21% O2. b, Hit list of metabolic 
genes. c, d, NMCs transduced as indicated (c) and ventricular samples from sham- and 
1K1C-treated mice (d) were analysed for Khk-A and Khk-C expression by RT–PCR and 
HincII digestion. Primers to amplify the KHK variable region are indicated (c, upper). The 
hypothetical HIF1α–SF3B1–KHK-C axis (c, right). e, Ventricular samples from sham- and 
1K1C-treated mice and lysates of NMCs overexpressing KHK-A or KHK-C were processed 
for immunoblotting with antibodies against denoted proteins. A and C indicate the 
differential migration of KHK-C and KHK-A on SDS gels. f, Biopsies of left ventricles 
from aortic stenosis patients and healthy controls were assessed for SF3B1, KHK-A and 
KHK-C expression by qPCR (n = 16 for patient samples and n = 6 for controls; error bars 
are s.e.m.; **P < 0.01; ***P < 0.001; two-tailed unpaired t-test). g, Top, schematic 
representation of exon 2 to 5 of human KHK. Alternative usage of exon 3 (Ex3 alt.) is 
displayed in blue (exon 3A) and red (exon 3C). Primer sets location and orientation used for 
RT–PCR analysis, are indicated with arrows. Bottom, assessment of KHK-A and KHK-C 
expression by RT–PCR in ventricles of controls and HCM patients using primer set 1 and 2 
as described above. h, Lysates of left-ventricular samples from healthy controls and aortic 
stenosis or HCM patients were processed for immunoblotting with antibodies against 
denoted proteins.
Mirtschink et al. Page 37
Nature. Author manuscript; available in PMC 2016 March 09.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Figure 2. SF3B1 is a HIF1α-target gene that mediates splicing of KHK
a, Co-transfection of wild type (WT) or HRE-mutated SF3B1 promoters fused to luciferase 
with either an empty vector control or HIF1αΔODD (values are relative light units (r.l.u.); n 
= 4 biological replicates per group). b, NMCs were cultured as indicated and processed for 
chromatin immunoprecipitation with a HIF1α-specific antibody (IP: HIF1α) or with a 
control isotype-matched antibody (IgG control). c, Schematic representing branch-point 
sequences located in front of exon 3A (upper left) or exon 3C (lower left). Branch point 
adenine is labelled in red. Location and orientation of primers (arrows), expected length of 
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fragments to be amplified by RT–PCR and potential Sf3b1 binding sites are depicted. NMCs 
treated as indicated were processed for RNA-immunoprecipitation assay with antibodies 
specific for Sf3b1 (IP) or control-isotype matched antibody (IgG). Recovered RNA was 
purified and analysed by RT–PCR (upper right and lower right). d, Mass spectrometry-
based metabolomic profiling of NMCs transduced with lentiviruses as denoted focused on 
hexose-phosphates. Metabolite values are compared to amounts in control transduced NMCs 
(n = 4 biological replicates per group). e, KHK activity in lysates of NMCs transduced with 
lentiviruses as indicated (n = 7 biological replicates per group). f, Relative amount of 
[13C]fructose-1-phosphate derived from [13C]fructose ([13C]frc) or [13C]glucose ([13C]glc) 
in NMCs transduced as denoted (n = 4 biological replicates per group). g, [3H]leucine 
incorporation in NMCs infected as indicated (n = 3 biological replicates per group, data 
show 1 of 3 representative experiments). For panels a, e–g, *P < 0.05; **P < 0.01; ***P < 
0.001. Two-tailed unpaired t-test (a) one-way ANOVA followed by Dunnett’s multiple 
comparison post-test (e–g). Error bars are s.d. (a, g) or s.e.m. (e, f).
Mirtschink et al. Page 39
Nature. Author manuscript; available in PMC 2016 March 09.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Figure 3. Anabolic metabolism and growth as a function of KHK-C
Untargeted analysis of metabolites in NMCs treated as denoted. Depicted are metabolites 
with log2(fold change) > 0.5 and adjusted P value < 0.01 in at least one treatment group 
compared to corresponding control (n = 4 biological replicates per group).
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Figure 4. SF3B1 is required for pathologic cardiac growth and function
a, Schematic representation of the AAV9-fl/fl-shSf3b1 virus before and after Cre-mediated 
recombination (left panel) and of the experimental timeline (right panel). b–d, Left-
ventricular weight normalized to tibia length (LV/TL) (b), isovolumic relaxation time 
(IVRT) (c) and ventricular fructose levels (d) of sham- or 1K1C-treated Mlc2v-cre− and 
Mlc2v-cre+ mice injected with AAV9-fl/fl-shSf3b1#1 viruses. e, Immunoblots of heart 
lysates from Mlc2v-cre− and Mlc2v-cre+ mice operated and transduced as in b–d using 
indicated antibodies. f, g, LV/TL (f) and ejection fraction (EF) (g) of sham- or TAC-treated 
Mlc2v-cre− and Mlc2v-cre+ mice injected as indicated. h, Lysates of hearts from mice 
transduced and operated as in f were processed for immunoblotting with antibodies against 
denoted proteins. For a–d, f, g, number of mice per group is given in Extended Data Table 
1. Error bars are s.e.m. *P < 0.05; **P < 0.01; two-tailed unpaired t-test (b–d, f, g).
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Figure 5. Khk-A/C−/− mice are protected from pathologic cardiac growth and contractile 
dysfunction
a–c, Left-ventricular weight normalized to tibia length (LV/TL) (a), representative images 
of left ventricles (b) and isovolumic relaxation time (IVRT) (c) of sham- or 1K1C-operated 
Khk-A+/+ and Khk-A−/− mice. d, Lysates from ventricles of sham- or 1K1C-operated Khk-
A+/+ and Khk-A−/− mice were processed for immunoblotting with antibodies as indicated. e–
g, Left-ventricular weight normalized to tibia length (e), representative images of left 
ventricles (f) and isovolumic relaxation time (g) of sham- or 1K1C-operated Khk-A/C+/+ and 
Khk-A/C−/− mice. h, Lysates from ventricles of sham- or 1K1C-operated Khk-A/C+/+ and 
Khk-A/C−/− mice processed for immunoblotting with antibodies as indicated. For a, c, e, g, 
*P < 0.05; **P < 0.01; ***P < 0.001; two-tailed unpaired t-test; number of mice per group 
is given in Extended Data Table 2. Error bars are s.e.m.
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